METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC)
Clinical trials for METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC) explained in plain language.
Never miss a new study
Get alerted when new METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC) trials appear
Sign up with your email to follow new studies for METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
German study tracks new combo therapy for advanced prostate cancer
Disease control Not yet recruitingThis study will follow 500 men in Germany with metastatic hormone-sensitive prostate cancer (mHSPC) who are taking darolutamide plus standard hormone therapy. The main goal is to see how many men have very low PSA levels after 12 months. Researchers will also track survival and h…
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC)
Sponsor: Bayer • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
Could surgery after meds tame tough prostate cancer?
Disease control Not yet recruitingThis study tests whether men with advanced prostate cancer that has spread to other parts of the body can benefit from having their prostate removed after initial drug therapy. Participants first receive 6 months of hormone-blocking drugs. Those whose scans show the cancer has qu…
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC)
Phase: PHASE2 • Sponsor: Fudan University • Aim: Disease control
Last updated May 05, 2026 11:56 UTC